Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

8 treatments under study, led by Genetic Analysis Of Nlrp3

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 1 (1)
Phase 3 (1)

Trial Status

Completed2
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06544018Not ApplicableRecruiting

Circadian Rhythm Deregulation in Patients With CAPS

NCT00214851Phase 1CompletedPrimary

The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria

NCT00288704Phase 3Completed

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Showing all 3 trials

Research Network

Common Treatments

  • Genetic Analysis Of Nlrp31
  • Aidai Score1
  • Saliva Sampling1
  • Questionnaire1
  • Blood Sampling1

Active Sponsors

  • Atlantic Provinces Dermatology Association1
  • Nova Scotia Health Authority1
  • Regeneron Pharmaceuticals, Inc.1
  • Hospices Civils de Lyon1

Top Investigators

Related Conditions

  • Cinca Syndrome1
  • Mucklewells Syndrome1
  • Mucklewells Syndrome Mws1
  • Familial Cold Autoinflammatory Syndrome Fcas1
  • Genetic Diseases Inborn1

Activity Timeline